Table 3

Discrimination quality AUROCa (with CI 95%) and integrated discrimination improvement (IDI), after addition of 32 or 18 single nucleotide polymorphisms (SNPs) to the null model and the covariate model, in different disease strata

Genetic EffectER+ER−PR+PR−Early diagnosisLate diagnosis
# Cases in full data392010592953138113163747
No covariates
 +32 SNPs0.596 (0.574–0.618)0.530 (0.493–0.568)0.598 (0.573–0.622)0.560 (0.527–0.594)0.609 (0.573–0.645)0.574 (0.553–0.596)
 IDI0.208%0.047%0.208%0.101%0.115%0.191%
 +18 SNPs0.595 (0.574–0.617)0.530 (0.492–0.567)0.597 (0.573–0.621)0.560 (0.526–0.593)0.610 (0.574–0.645)0.574 (0.552–0.596)
 IDI0.199%0.050%0.197%0.095%0.114%0.192%
 Covariate model*0.570 (0.547–0.592)0.544 (0.507–0.581)0.570 (0.545–0.595)0.544 (0.510–0.579)0.540 (0.502–0.577)0.562 (0.539–0.584)
 +32 SNPs0.618 (0.596–0.639)0.553 (0.516–0.590)0.619 (0.595–0.643)0.580 (0.547–0.614)0.615 (0.579–0.651)0.594 (0.572–0.616)
 IDI0.215%0.051%0.216%0.108%0.125%0.202%
 +18 SNPs0.618 (0.596–0.639)0.554 (0.517–0.591)0.619 (0.595–0.643)0.582 (0.549–0.615)0.615 (0.579–0.651)0.595 (0.573–0.616)
 IDI0.204%0.054%0.207%0.099%0.120%0.202%
  • *Including parameters on age at menarche, at first birth and at menopause and count of births, BMI, alcohol consumption, smoking and use of hormone replacement therapy.

  • ER, Oestrogen receptor; PR, progesterone receptor.